Clarity Pharmaceuticals (ASX:CU6) combined trastuzumab with its proprietary copper-chelating, or SAR, technology for the development of copper-67-based radioimmunotherapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, according to a Tuesday Australian bourse filing.
Preclinical evidence showed a dose-response reduction in tumor size and prolonged survival using copper-67-SAR-trastuzumab compared to trastuzumab, an antibody that targets HER2, alone in a HER2-positive tumor mouse model, the filing said.
The firm collaborated with the University of Melbourne for the combination of the trastuzumab antibody with the SAR chelator and radiolabeling with copper-64 for diagnostic imaging, the filing added.
The firm plans to conduct a phase 1/2a theranostic study with copper-64 and copper-67 SAR trastuzumab in HER2-positive breast cancer patients, per the filing.
It also signed a supply agreement with EirGenix for the clinical development and future commercial supply of clinical-grade good manufacturing practice trastuzumab biosimilar, EG12014.
Its shares fell 6% in early trading on Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。